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Oligomeric forms of amyloid-b peptide (Ab) are
thought to play a pivotal role in the pathogenesis
of Alzheimer’s disease (AD), but the mechanism
involved is still unclear. Here, we generated induced
pluripotent stem cells (iPSCs) from familial and
sporadic AD patients and differentiated them into
neural cells. Ab oligomers accumulated in iPSC-
derived neurons and astrocytes in cells from patients
with a familial amyloid precursor protein (APP)-
E693D mutation and sporadic AD, leading to endo-
plasmic reticulum (ER) and oxidative stress. The
accumulated Ab oligomers were not proteolytically
resistant, and docosahexaenoic acid (DHA) treat-
ment alleviated the stress responses in the AD neural
cells. Differential manifestation of ER stress and DHA
responsiveness may help explain variable clinicalresults obtained with the use of DHA treatment and
suggests that DHA may in fact be effective for a
subset of patients. It also illustrates how patient-
specific iPSCs can be useful for analyzing AD patho-
genesis and evaluating drugs.
INTRODUCTION
Alzheimer’s disease (AD) is the most prevalent neurodegenera-
tive disorder. One of the pathological features of AD is the
oligomerization and aggregation and accumulation of amyloid-
b peptide (Ab), forming amyloid plaques in the brain. Cognitive
impairment observed in clinical AD is inversely well correlated
with the amount of Ab oligomers in the soluble fraction rather
than the amount of Ab fibrils (amyloid plaques) constituting the
oligomers (Haass and Selkoe, 2007; Krafft and Klein, 2010).
Increasing evidence has shown that Ab oligomers extracted
from AD model mice or made from synthetic peptides causeCell Stem Cell 12, 487–496, April 4, 2013 ª2013 Elsevier Inc. 487
Figure 1. Establishment of Control and AD Patient-Specific iPSCs, and Derivation of Cortical Neurons Producing Abs from iPSCs
(A) Established iPSCs from both controls and AD patients showed embryonic stem cell-like morphology (Phase) and expressed pluripotent stem cell markers
NANOG (red) and TRA1-60 (green). The scale bar represents 200 mm.
(B) Genomic DNA sequences showed the presence of the homozygous genotype for E693 deletion and the heterozygous genotype for V717L mutation on the
APP gene only in AD iPSCs.
(C) Estimation of neuronal differentiation from control and AD-iPSCs. After 2 months of differentiation, neurons were immunostained with antibodies against the
neuronal marker TUJ1 and the cortical neuron markers TBR1 and SATB2. The scale bar represents 30 mm.
(D) Proportions of TUJ1-, TBR1-, and SATB2-positive cells in control and AD-iPSCs. Data represent mean ± SD (n = 3 per clone).
(E) Ab40 and Ab42 secreted from iPSC-derived neural cells into the medium (extracellular Ab) were measured at 48 hr after the last medium change. Data
represent mean ± SD (n = 3 per clone). Levels of Ab40 and Ab42 in AD(APP-E693D) without b-secretase inhibitor IV (BSI, 1 mM) were significantly lower than
those of the others (*, p < 0.006), and the level of Ab42 and the ratio of Ab42/Ab40 in AD(APP-V717L) without BSI were significantly higher than those of the others
(legend continued on next page)
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(Walsh et al., 2002; Gong et al., 2003; Lesne´ et al., 2006), and
this was also true in humans (Kuo et al., 1996; Shankar et al.,
2008; Noguchi et al., 2009). Therefore, the formation and accu-
mulation of Ab oligomers has been presumed to play a central
role in the pathogenesis and clinical symptoms of AD. Abs are
composed of 38–43 amino acid residues and are generated
from the amyloid precursor protein (APP) by b- and g-secre-
tase-mediated sequential cleavages. A number of mutations
linked to familial AD in the APP gene have been identified.
Recently, an atypical early-onset familial AD, caused by an
E693D mutation of an APP-producing variant Ab lacking 22nd
Glu was discovered in Japan (Tomiyama et al., 2008). This
APP-E693Dmutation presents rare, autosomal-recessive muta-
tions of the APP gene related to familial AD. Patients with the
mutation show overt early-onset symptoms of AD but lack Ab
deposition, according to positron emission tomography (PET)
scan analysis with a [11C] Pittsburgh compound-B (PIB) radiop-
robe (Tomiyama et al., 2008; Shimada et al., 2011). The 22nd Glu
within the Ab sequence has a destabilizing effect on the forma-
tion of oligomeric structures because of the electrostatic repul-
sion between the adjacent side chain of 22nd Glu (Kassler
et al., 2010), and the deletion of the amino acid residue leads
to the ready formation of Ab oligomers in vitro (Nishitsuji et al.,
2009). APP-E693D transgenic mice show AD-like pathology,
including intracellular oligomer accumulation, but lack extracel-
lular amyloid plaque formation (Tomiyama et al., 2010). However,
it remains unclear whether Ab oligomers are accumulated in
familial and sporadic AD patient neural cells and how intracellular
Ab oligomers play a pathological role. The compound and/or
drugs that might rescue the Ab oligomer-induced pathological
phenotypes are also unclear. Recent developments in induced
pluripotent stem cell (iPSC) technology have facilitated the
investigation of phenotypes of patient neural cells in vitro and
have helped to overcome the lack of success in modeling
sporadic AD.
Here, we report the derivation and neuronal and astroglial
differentiation of iPSCs from a familial AD patient with an
APP-E693D mutation, a familial case with another APP muta-
tion, as well as other sporadic cases. Using patient neurons
and astrocytes, we addressed the accumulation and possible
pathological roles of intracellular Ab oligomers in familial and
sporadic AD. We found that Ab oligomers were not proteo-
lytically resistant and that docosahexaenoic acid (DHA) treat-
ment attenuated cellular phenotypes of AD neural cells with
intracellular Ab oligomers in both familial and sporadic AD
patients.
RESULTS
iPSC Generation and Cortical-Neuronal Differentiation
Dermal fibroblasts were reprogrammed by episomal vectors
(Okita et al., 2011). Control iPSC lines from three unrelated indi-(*, p < 0.001). There are significant differences between dimethyl sulfoxide (DMSO
E693D) for Ab42.
(F) Ab40 and Ab42 in cell lysates (intracellular Ab). N.D., not detected. Data repre
(G) The amount of soluble APPb was not altered in control and AD. Data represe
See also Figure S1.viduals, three and two familial AD iPSC lines from patients with
E693D[AD(APP-E693D)] and V717L[AD(APP-V717L)] APP muta-
tions, respectively, and two sporadic iPSC lines (AD3E211 and
AD8K213) from two unrelated patients (Figure S1A available
online) were generated (Figures 1A, 1B, and S1B–S1H). To char-
acterize cortical neurons derived from the iPSC lines, we estab-
lished differentiation methods for cortical neurons by modifying
previous procedures (Morizane et al., 2011) (Figure S1I). The
differentiated cells expressed the cortical neuron subtype
markers SATB2 and TBR1 (Figure 1C), and the differentiated
neurons were functionally active (Figures S1J and S1K). There
was no prominent difference in the differentiation propensity
between control and AD neurons (Figures 1D and S1L).
We analyzed the amounts of extra- and intracellular Ab40 and
Ab42 (Figures 1E and 1F). As expected, both Ab species were
strongly decreased in all cloned AD(APP-E693D) neural cells in
comparison to those in control neural cells. In familial AD(APP-
V717L) neural cells, an increase in the extracellular Ab42 level
and a corresponding decrease in the intracellular Ab42 level
were observed, and the Ab42/Ab40 ratio in the culture medium
was increased up to 1.5-fold, suggesting that the abnormality
of APP metabolism in AD is dependent on the mutation sites in
APP. Extracellular Ab levels in sporadic AD neural cells were
not changed in comparison to those in control neural cells, but
intracellular Ab in sporadic AD8K213 neural cells apparently
decreased (that is, below the detection limit). APP expression
levels in the AD(APP-E693D) neural cells were lower than in the
others, but the levels of a- and b-secretase-mediated APP pro-
cessing remained unaltered in all neural cells (Figures 1G,
S1M, and S1N). Soluble APPb production was strongly inhibited
by treatment with b-secretase inhibitor IV (BSI) (Figure 1G). Ab
levels in the original fibroblasts and iPSC-derived astrocytes, in
which APP expression levels were relatively higher than those
in neural cells (data not shown), were lower than those of the cor-
responding neural cells (Figures S1O and S1P).
Intracellular Accumulation of Ab Oligomers in AD(APP-
E693D) and in One of the Sporadic AD Neural Cells
Using an immunocytochemical method with the Ab-oligomer-
specific antibody NU1 (Lambert et al., 2007), we investigated
whether AD(APP-E693D) neural cells harbor Ab oligomers or
not. We found that Ab oligomers were accumulated as puncta
in the neurons of AD(APP-E693D) and in one of the sporadic
AD cases (Figure 2A). The area of Ab-oligomer-positive puncta
was significantly increased in AD(APP-E693D) neuronal cells
relative to control neuronal cells (Figure 2B). Dot blot analysis
using cell lysates revealed that Ab oligomers were markedly
elevated in the AD(APP-E693D) and sporadic AD8K213 neural
cells (Figures 2C and 2D), whereas Ab oligomers were not de-
tected in the culture medium (data not shown). Another antibody
against Ab, 11A1, which detects low-molecular-weight oligo-
mers rather than the Ab monomer (Murakami et al., 2010),
showed results similar to those observed with NU1 (Figures)-control and BSI treatment in each case (*, p < 0.001) except that of AD(APP-
sent mean ± SD (n = 3 per clone).
nt mean ± SD (n = 3 per clone).
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Figure 2. Familial AD(APP-E693D) and Sporadic AD iPSC-Derived Neurons Have Intracellular Ab Oligomers
(A) Intracellular Ab oligomer accumulation in iPSC-derived neurons (red, MAP2-positive cells) was detected by the Ab-oligomer-specific monoclonal antibody
NU1 (green) with a punctate pattern. Ab oligomer accumulation was massive in AD(APP-E693D) and sporadic AD(AD8K213) neurons but only faint in control
neurons. Treatment with 1 mM BSI decreased Ab oligomer accumulation. DAPI, nuclear staining (blue). The scale bar represents 30 mm.
(B) Quantification of Ab oligomer accumulation in (A); the ratio of the NU1-positive area in the MAP2-positive area was analyzed. Data represent mean ± SD (n = 3
per clone). Ab oligomer levels in the AD(APP-E693D) and sporadic AD(AD8K213) neural cells without BSI were significantly different from those of other neural
cells (*, p < 0.005) and from corresponding neural cells with BSI (#, p < 0.005).
(C) Dot blot analysis with the use of NU1 antibody. Control (N116213, N117322, 409B2), APP-E693D(APP1E111, APP1E211, APP1E211), APP-V717L (APP2E22,
APP2E26), and sporadic AD (AD3E211, AD8K213) neural cells were dotted from the left. Blank is RIPA buffer only.
(D) Signals of blot in (C) were quantified. Data represent mean ± SD (n = 3 per clone). Ab oligomer levels in AD(APP-E693D) and sporadic AD(AD8K213) neurons
without BSI were significantly different from those of other neurons (*, p < 0.001) and from corresponding neurons treated with 1 mM BSI (#, p < 0.001).
(E) Ab oligomer accumulation in AD astrocytes. The scale bar represents 30 mm.
(legend continued on next page)
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lysates from the fibroblasts that generate iPSC lines (Figure S2E).
To confirm whether Ab oligomers were derived from mutant
APP(E693D), we transduced a lentiviral vector driven by an
EF1a promoter to overexpress wild or mutant APP(E693D) in
control iPSC-derived neural cells and found that Ab oligomers
emerged inside control neural cells overexpressing mutant
APP(E693D) (Figure S2F).
To investigate the intracellular accumulation of Ab oligomers in
astrocytes derived from control and AD iPSCs, we established
an astrocyte-enrichment culture by modifying the method previ-
ously reported (Krencik et al., 2011) (Figures S2G–S2J). Dot blot
analysis using Ab oligomer antibodies revealed that the astro-
cytes of AD(APP-E693D) and one of the sporadic AD iPSCs
accumulated Ab oligomers intracellularly (Figures 2E, S2K, and
S2L), which was compatible with the results of neurons. On the
other hand, we detected no difference in the uptake of extracel-
lular glutamate between control and AD astrocytes (Figure S2M).
Ab oligomers were also detected as a protein band with a
molecular mass of 5060 kDa by western blot analysis (Figures
2F and S2N). The accumulation of Ab oligomers was inhibited by
treatment with BSI (Figures 2A–2G, S2A–S2D, and S2N). To
clarify whether the E693D mutation results in accelerated Ab
oligomerization and/or in a proteolytically resistant and stable
form of Ab oligomers, we analyzed the levels of Ab oligomers
over a course of time after BSI treatment. Intracellular Ab oligo-
mers started to disappear from 2 hr after the treatment with
BSI, almost reaching the control level by 8 hr (Figures 2G and
2H). Secretion of Ab40 from control neural cells was already in-
hibited at 2 hr after BSI treatment, but the secretion from AD
neural cells was under the detection limit in both the presence
and absence of BSI (Figure 2I).
Cellular Stress Responses Caused By Intracellular Ab
Oligomers in AD iPSC-Derived Neural Cells
Extracellular Ab deposition in patient brains carrying APPwith an
E693D mutation is predicted to be extremely low, as amyloid
PET imaging with a [11C] PIB probe revealed a far lower signal
in the patients than those observed in sporadic AD brains
(Tomiyama et al., 2008). Given that processing by b- and g-sec-
retases largely proceeds within vesicular endosomal compart-
ments, it was possible that Ab oligomers were associated with
specific organelles. We characterized the Ab oligomer-positive
punctate structures in AD(APP-E693D) neural cells and astro-
cytes by coimmunostaining with antibodies for markers of
vesicular compartments and subcellular organelles. Subpopula-
tions of Ab oligomer-positive puncta in the AD neurons showed
positive immunostaining for an endoplasmic reticulum (ER)
marker, binding immunoglobulin protein (BiP); an early endoso-
mal marker, early endosome-associated antigen-1 (EEA1); and(F) Western blot analysis of control and AD neural cells in the presence or absen
bands in cell lysates of AD(APP-E693D) and sporadic AD(AD8K213) neural cells.
(G) Disappearance of Ab oligomers after BSI treatment was analyzed by dot blot
disappear 2 hr after BSI treatment.
(H) Signals of blots in (G) were quantified. Data represent mean ± SD (n = 3 per clo
reduced to 1623% of vehicle control by 8 hr. Post hoc analysis revealed tha
decreased in comparison to those of DMSO control oligomers (*, p < 0.005).
(I) Changes in extracellular Ab40 levels were analyzed in the experimental condit
See also Figure S2.a lysosomal marker, lysosomal-associated marker protein 2
(LAMP2) (data not shown).
To uncover molecules that might be implicated in the dysfunc-
tion of AD(APP-E693D) neural cells, we analyzed gene expres-
sion profiles of control and AD neural cells (Figure 3A and Table
S1). Gene ontology analysis revealed that oxidative-stress-
related categories, including peroxiredoxin, oxidoreductase,
and peroxidase activities, were upregulated in the AD, whereas
glycosylation-related categories were downregulated (Figures
3B and 3C and Table S1), suggesting that ER and Golgi function
might be perturbed in AD neural cells. Western blot analysis clar-
ified that the amounts of both BiP and cleaved caspase-4 were
elevated in the neurons and astrocytes of the AD(APP-E693D)
case, and that of BiP in one of the sporadic AD cases,
AD8K213, but not in fibroblasts (Figures 3D–3F and S3A–S3F).
We also found that BSI treatment not only prevented the
increase in Ab oligomer-positive puncta area per cell in the
context of AD(APP-E693D) lines but also decreased the amount
of BiP and cleaved caspase-4 (Figures 3D–3F). PRDX4-coding
antioxidant protein peroxiredoxin-4 was the most highly upregu-
lated gene (Figure 3C). Western blot analysis confirmed that the
amount of peroxiredoxin-4 was increased up to approximately
5- to 7-fold in lysates from AD(APP-E693D) and in one of the
sporadic AD cases, AD8K213 neural cells, but not in fibroblasts,
and was decreased by the BSI treatment (Figures 3D, 3G, S3A,
S3D, S3G, and S3H), indicating that the antioxidant stress
response was provoked by Ab oligomer formation in AD(APP-
E693D) and sporadic AD8K213. To identify pathogenic species
evoking oxidative stress in AD(APP-E693D), we visualized reac-
tive oxygen species (ROS) and found that ROS was increased in
both neurons and astrocytes in AD(APP-E693D) and AD8K213
(Figures 3H–3J and S3I –S3L). This increase was counteracted
by the BSI treatment. These results indicated that intracellular
Ab oligomers provoked both ER and oxidative stress, and the
increase in ROSmost likely occurred via a vicious cycle between
ER and oxidative stress (Malhotra and Kaufman, 2007).
Alleviation of Intracellular AbOligomer-InducedCellular
Stress by DHA
We evaluated BSI and three additional drugs that had been re-
ported to improve ER stress or to inhibit ROS generation: (1)
DHA (Begum et al., 2012), (2) dibenzoylmethane (DBM14-26)
(Takano et al., 2007), and (3) NSC23766 (Lee et al., 2002) (Figures
4 and S4). DHA treatment significantly decreased the protein
level of BiP, cleaved caspase-4, and peroxiredoxin-4 in AD
(APP-E693D) neural cells (Figures 4A, 4B, S4A, and S4B), and
BiP and peroxiredoxin-4 in sporadic AD8K213 (Figures S4C
and S4D). Furthermore, DHA treatment also decreased the
generation of ROS in AD(APP-E693D) neural cells (Figures 4C
and 4D), whereas the amount of Ab oligomers in cell lysatesce of BSI. BSI treatment (1 mM) disappeared 6E10-positive z55 kDa protein
analysis with the use of the NU1 antibody. Intracellular Ab oligomers started to
ne). BSI treatment (1 mM) decreased intracellular Ab in AD neural cells and was
t the amounts of Ab oligomers at 2 hr after BSI treatment were significantly
ion of (G). Data represent mean ± SD (n = 3 per clone).
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Figure 3. Cellular Stress Responses Caused by Intracellular Ab Oligomers in Familial AD(APP-E693D) and Sporadic AD(AD8K213) iPSC-
Derived Neural Cells
(A) Hierarchical clustering analysis of differentiated neuronal cells and a heatmap of significantly up- and downregulated genes in AD neural cells. The statistically
significant cutoff p value is < 0.05.
(legend continued on next page)
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tration of DHA, DBM14-26, or NSC23766 treatment increased
the protein level of BiP (Figure S4B). Finally, to confirm the
protective effects of DHA in short-term screening, we analyzed
the effect on the survival of AD(APP-E693D) neural cells.
Neuronal cells were labeled with a lentiviral vector express-
ing synapsin I-promoter-driven EGFP and cultivated in the
medium depleted of neurotrophic factors and neural culture
supplements mix. The real-time survival rate of AD(APP-
E693D) neurons was lower than that of normal control neurons;
however, DHA treatment for 16 days partially rescued AD(APP-
E693D) cell viability (Figures 4E–4G). The real-time survival rate
of sporadic AD(AD3E211, AD8K213) neurons for 16 days was
unchanged (Figures 4E and 4F and Table S2). We confirmed
these results through a lactate dehydrogenase (LDH) assay
(Figure 4G). The AD(APP-E693D) neurons were also vulner-
able to oxidative stress by hydrogen peroxide treatment (Fig-
ure S4H). Extracellular Ab levels were not altered in the assay
(Figure 4H).
DISCUSSION
The present study shows that neural cells derived from a patient
carrying the pathogenic APP-E693Dmutation and a sporadic AD
patient produce intracellular Ab oligomers, and the use of these
neural cells provided an experimental system for addressing
whether such oligomers would cause cellular stress and the
killing of neurons and how such intracellular Ab oligomers might
contribute to the disease pathogenesis, despite only one patient
carrying the E693D mutation being available. Our findings also
suggest that the possible heterogeneity of familial and sporadic
AD stems from phenotypic differences of intracellular Ab oligo-
mers and suggests the possibility that DHA, a drug that failed
in some clinical trials of AD treatment, might be effective in a
portion of AD patients.
We demonstrated that Ab oligomers were formed and accu-
mulated inside AD(APP-E693D) and sporadic AD(AD8K213)
neurons by immunostaining (Figures 2A and 2B), dot blot anal-
ysis (Figures 2C and 2D), and western blot analysis (Figures 2F
and S2N). In addition, intracellular accumulation of Ab oligo-
mers, which has been supposed to be proteolytically resistant,
disappeared after treatment with BSI in both AD neurons
(Figures 2G and 2H), indicating that AD(APP-E693D) and
sporadic AD(AD8K213) neurons still seemed to retain a degrad-
ing activity toward Ab oligomers in which proteasomes, auto-(B) The gene ontology (GO) term list, calculated from the significantly altered ge
cells.
(C) Altered expression levels of genes related to peroxidation activity detected
(p < 0.05).
(D–G) Western blot analysis of ER stress markers (BiP and casapase-4), peroxir
(E–G) Densitometric analysis of (D) are shown. Measured values of proteins were n
(E), cleaved caspase-4 (F), and peroxiredoxin-4 (G) in AD(APP-E693D) and sporad
of the other neural cells (**, p < 0.005).
(H) Typical images of reactive oxygen species (ROS) staining, detected byHPF or C
represent 30 mm.
(I and J) Quantitative data of (H), ROS-HPF (I), and ROS-CellROX (J). Each value w
fields per sample) adjusted with DAPI counts. Data represent mean ± SD (n = 3 pe
neural cells were significantly different from those of the others (**, p < 0.001). D
See also Figure S3 and Table S1.phagosomes, and/or lysosomes may be involved and, thereby,
that the pathological property of Ab oligomers in a part of AD
might be completely abrogated. The sporadic AD(AD8K213)
neurons may retain a specific cellular environment that per-
mits the formation of Ab oligomers. Additional studies aimed
at identifying the factors causing such an environment are
needed.
We observed that the accumulation of Ab oligomers induced
ER and oxidative stress both in AD(APP-E693D) and in sporadic
AD(AD8K213) neurons, although caspase-4 activation appeared
not to accompany sporadic AD, probably because of the lesser
extent of ER stress in comparison to AD(APP-E693D). Previ-
ously, Nishitsuji et al. (2009) reported that accumulated Ab
oligomers in ER provoke ER stress. This result suggests that
oligomers represent a self-aggregating state of Ab. During this
process, Ab generates ROS, which is supported by the fact
that Ab coordinates the metal ions zinc, iron, and copper, which
induce the oligomerization of Ab. Iron and copper then cause the
generation of toxic ROS and calcium dysregulation (Barnham
et al., 2004), leading to membrane lipid peroxidation and the
impairment of the function of a range of membrane-associated
proteins (Hensley et al., 1994; Butterfield, 2003), antioxidant
factors being thought to protect ER-stress-induced cellular
toxicities (Malhotra and Kaufman, 2007).
We found that intracellular Ab oligomers were accumulated
not only in a case of familial AD with APP-E693D mutation but
also in a sporadic AD case, although only three clones derived
from one familial AD patient carrying an APP-E693D mutation
and two clones from two sporadic AD patients were analyzed
in this study because of the limited number of patients. In
contrast, in familial AD with the APP-V717L mutation, of which
only one case was available, intracellular Ab oligomers were
not detected, but the extracellular Ab42/Ab40 ratio, which is
increased in mutant presenilin-mediated familial AD, as reported
previously (Yagi et al., 2011), was increased, lending support to
the notion that AD could be classified into two categories: extra-
cellular Ab type and intracellular Ab type. Although it has been
supposed that environmental factors and/or the aging process
contribute to neurodegenerative diseases, our findings support
the idea that a genetic factor might play a role in a part of
sporadic AD, a finding that is compatible with a previous report
(Israel et al., 2012). However, identifying the genetic factor would
require a larger sample size. The sporadic AD case with intracel-
lular Ab oligomers might correspond to the case without extra-
cellular Ab40 elevation of Israel et al. (2012). Analysis of neuronsne expression patterns in the microarray analysis of AD versus control neural
by GO analysis. All values were significantly different from that of the control
edoxin-4, and a reference protein (b-actin) in the presence or absence of BSI.
ormalized by b-actin. Data represent mean ± SD (n = 3 per clone). Levels of BiP
ic AD(AD8K213) neural cells without BSI were significantly different from those
ellROX, in control and AD neural cells with or without BSI treatment. Scale bars
as shown as a ratio of the HPF-stained or CellROX area (average of random 25
r clone). ROS-generation levels in AD(APP-E693D) and sporadic AD(AD8K213)
ata represent mean ± SD (n = 3 per clone).
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Figure 4. DHA-Alleviated Cellular Stress Caused By Intracellular Ab Oligomers
(A) Control and AD(APP-E693D) neural cells at day 72 were treated with DHA for 48 hr. Then, cells were lysed and subjected to immunoblot analysis (1 mM, 5 mM,
and 15 mM of docosahexaenoic acid [DHA]).
(B) Densitometric analysis of (A) is shown. Measured values were normalized by that of b-actin. Data represent mean ± SD (n = 3 per clone). Two-way analysis of
variance (ANOVA) showed significant main effects of DHA treatment (BIP, F[3,64] = 136.712, p < 0.001; cleaved caspase-4, F[3,64] = 50.855, p < 0.001) with
a significant interaction between APP mutation and DHA treatment (BIP, F[3,64] = 99.658, p < 0.001; cleaved caspase-4, F[3,64] = 53.005, p < 0.001). Post hoc
analysis revealed significant differences between DMSO (control) and DHA treatment (1, 5, and 15 mM) in AD(APP-E693D) neural cells (**, p < 0.001). Two-way
ANOVA for peroxiredoxin-4 showed significant main effects of DHA treatment (F[3,64] = 16.995; p < 0.001) with a significant interaction between APPmutation and
DHA treatment (F[3,64] = 32.093; p < 0.001). Post hoc analysis revealed significant differences between DMSO-control and DHA treatment (5 and 15 mM) in
AD(APP-E693D) neural cells (**, p < 0.001). In control neural cells, the 5 mM DHA group was significantly different from the other groups (#, p < 0.005).
(C) Typical images of ROS-CellROX and Hoechst33342 signals after treatment with vehicle or 5 mM DHA. The scale bar represents 50 mm.
(legend continued on next page)
Cell Stem Cell
Modeling Alzheimer’s Disease with Patient iPSCs
494 Cell Stem Cell 12, 487–496, April 4, 2013 ª2013 Elsevier Inc.
Cell Stem Cell
Modeling Alzheimer’s Disease with Patient iPSCsand astrocytes, as we performed here, from larger numbers of
patients might result in the classification of sporadic AD.
To date, the clinical effectiveness of DHA treatment is still
controversial (Freund-Levi et al., 2006; Quinn et al., 2010). It is
of particular interest that one of two sporadic AD neurons accu-
mulated intracellular Ab oligomers and showed cellular pheno-
types that could respond to DHA but the other did not, and this
result may explain why DHA treatment was effective for some
AD patients, those with the intracellular Ab oligomer-associated
type of AD, although the timing (that is, the stage of disease
development) for starting the treatment would be another critical
factor. These results may suggest that patient-specific iPSCs
provide a chance to re-evaluate the effect of a drug that failed
in AD clinical trials, depending on the selection of the patient
type. In the present study, the amount of Ab oligomers in our
culture was not affected by DHA, although it would be effective
for reducing cellular stresses, and reducing the oligomerization
of Ab was also presumed to be a candidate mechanism of
DHA treatment (Cole and Frautschy, 2006). These results indi-
cate that therapy with DHA would alleviate symptoms. Further-
more, the data showing that BSI treatment leads to a reduction
in ROS formation at a relatively similar level (Figure 2G) in both
AD and control cells might indicate an Ab oligomer-independent
effect, in addition to an Ab oligomer-dependent effect, of BSI.
In any event, patient-specific iPSCs would provide disease
pathogenesis, irrespective of the disease being in a familial or
sporadic form, as well as enable the evaluation of drug and
patient classification of AD.
EXPERIMENTAL PROCEDURES
Derivation of Patient-Specific Fibroblasts
Control and AD-derived human dermal fibroblasts (HDFs) were generated
from explants of 3mmdermal biopsies. After 1–2weeks, fibroblast outgrowths
from the explants were passaged.
iPSC Generation
Human complementary DNAs for reprogramming factors were transduced in
HDFs with episomal vectors (SOX2, KLF4, OCT4, L-MYC, LIN28, and small
hairpin RNA for p53). Several days after transduction, fibroblasts were har-
vested and replated on an SNL feeder cell layer. On the following day, the
medium was changed to a primate embryonic stem cell medium (ReproCELL,
Japan) supplemented with 4 ng/ml basic FGF (Wako Pure Chemicals Indus-(D) Quantitative data of (C) is shown. Each value indicated the ratio of the CellROX
counts. Data represent mean ± SD (n = 3 per clone). Two-way ANOVA showe
a significant interaction between the APP mutation and DHA treatment (F[3,32] =
icantly different from the other groups (**, p < 0.005).
(E) Real-time survival rate of control and AD neural cells with and without DHA sh
Synapsin I-promoter-driven EGFP were sequentially imaged (average of 25 rando
Data represent mean ± SD (n = 3 per clone). In the cell-survival ratio, three-way AN
0.001), DHA treatment (F[1,256] = 36.117; p < 0.001), and time (F[7,256] = 65.272;
treatment (F[1,256] = 18.315; p < 0.001), between the APP mutation and time (F[7,2
0.001), and among all three factors (F[7,256] = 5.277; p < 0.001). Post hoc analysis
vulnerable in the long culture than control neural cells and that DHA treatment re
(F) Typical images of Synapsin::EGFP neurons used in real-time survival assay. T
(G) Cytotoxicity in neural culture derived from control and AD iPSCs after treatme
(LDH) release served as a measure of cytotoxicity. Data represent mean ± SD
treatment (F[1,32] = 16.710; p < 0.001) with a significant interaction between AP
a significant difference in AD(APP-E693D) neural cells between the DMSO-contr
(H) Ab40 and Ab42 secreted from iPSC-derived neurons into medium (extracellu
medium change. Data represent mean ± SD (n = 3 per clone).
See also Figure S4 and Table S2.tries, Japan). The medium was changed every other day. iPSC colonies
were picked up 30 days after transduction.
Statistical Analysis
All data are shown as mean ± SD. For comparisons of the mean between two
groups, statistical analysis was performed by applying Student’s t tests after
confirming equality between the variances of the groups. When the variances
were unequal, Mann-Whitney U tests were performed (SigmaPlot 11.2.0,
Systat Software, USA). Comparisons of the mean among three groups or
more were performed by one-way, two-way, or three-way analysis of variance
followed by a post hoc test with the use of Student-Newman-Keuls Method
(SigmaPlot 11.2.0). p values < 0.05 were considered significant.
ACCESSION NUMBERS
The Gene Expression Omnibus accession numbers for microarray data re-
ported in this paper are GSE43326 (gene-expression comparison between
control and AD clones), GSE43382 (gene-expression change along with the
astroglial differentiation), and GSE43328 (gene-expression comparison of
generated iPSCs).
SUPPLEMENTAL INFORMATION
Supplemental Information contains Supplemental Experimental Procedures,
four figures, and two tables and can be found with this article online at
http://dx.doi.org/10.1016/j.stem.2013.01.009.
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